Poland – Pharmaceutical products – Successive deliveries of medicinal products under Drug Programs, Chemotherapy, RDTL, General Medicines and Import for the needs of the Clinics/Departments of the Central Clinical Hospital of the Medical University of Łódź

Opportunity description

1. The subject matter of the contract is the successive delivery of medicinal products under Drug Programs, Chemotherapy, RDTL, General Medicines and Import for the needs of the Clinics/Departments of the Central Clinical Hospital of the Medical University of Łódź – at ul. Pomorska 251 2. The contract has been divided into 79 parts. 3. A detailed description of the subject matter of the contract is provided in Appendix No. 1 to the SWZ – Assortment and Price Form. 4. Time limit for fulfilling standard orders – within max. 48 hours (working days Mon–Fri) 5. Time limit for fulfilling urgent orders – within max. 24 hours (working days Mon–Fri). 6. Time limit for fulfilling “Life-Saving” orders – within max. 6 hours (the Contracting Authority requires the delivery of medicinal products in Life-Saving mode on Saturdays, Sundays and public holidays and a direct contact number for the person fulfilling the order on the Contractor’s side) – in the event of doubts as to whether a given medicine is treated by the Contracting Authority as a “life-saving” medicine (if applicable). 7. The above conditions do not apply to medicines imported under the named-patient import procedure. 8. The Contractor is obliged to perform the contract according to the rules and conditions described in the draft contract constituting Appendix No. 2 to the SWZ, depending on the part for which it submits a tender. 9. Shelf life of delivered products: a. for medicinal products, min. 12 months from the delivery date, unless the Contracting Authority indicated otherwise in the information below the table in the Price Form – Appendix No. 2 to the SWZ; b. for contrast agents, min. 12 months from the delivery date (if applicable); c. for medical devices, min. 12 months from the delivery date (if applicable); d. for enteral and parenteral nutrition products, food intended for infants and young children, and foodstuffs for special medical purposes, the remaining shelf life on the delivery date must be no shorter than half of the shelf life guaranteed by the manufacturer (if applicable). 10. Common Procurement Vocabulary CPV: 33690000-3 Various medicinal products 33600000-6 Pharmaceutical products 33692000-7 Medicinal solutions 11. The minimum value or volume of performance that the Contracting Authority undertakes to fulfil under the contract, in accordance with the assortment and price form. The option to increase the order by additional quantities must be taken into account, in accordance with the assortment and price form. 12. The Contracting Authority permits the submission of tenders for individual parts. The Contractor may submit a tender for one or more parts. 13. Any use of terms and proper names in the documentation is merely illustrative and serves to specify the class and quality of the materials. If the description of the subject matter of the contract contains references to trademarks, patents or origin, source or a particular process that characterises the products or services supplied by a specific Contractor, where this could lead to certain Contractors or products being favoured or eliminated, unless this is justified by the specific nature of the subject matter of the contract and the Contracting Authority cannot describe the subject matter of the contract using sufficiently precise terms, and such reference is accompanied by the words “or equivalent”., the Contractor may offer equivalent items. The Contracting Authority requires that the materials used, if different, have quality and technical parameters no worse than those specified in the subject matter of the contract. The burden of demonstrating the equivalence of the offered item rests with the Contractor. 14. The Contracting Authority does not permit the submission of variant tenders. 15. The Contracting Authority does not permit the submission of tenders in the form of electronic catalogues. 16. The Contracting Authority does not envisage concluding a framework agreement. 17. The Contracting Authority does not reserve the obligation for the Contractor to personally perform key parts of the contract. 18. The Contractor may entrust the performance of part of the contract to a subcontractor. The Contracting Authority requires the Contractor to indicate the parts of the contract that it intends to entrust to subcontractors and to provide the names of those subcontractors, if known at this stage of the procedure. 19. If a change or withdrawal of a subcontractor concerns an entity whose resources the Contractor relied upon, under the rules specified in Article 118(1) of the PZP Act, in order to demonstrate compliance with the conditions for participation in the procedure, the Contractor is obliged to demonstrate to the Contracting Authority that the proposed other subcontractor or the Contractor itself meets them to a degree no less than the subcontractor whose resources the Contractor relied upon during the procurement procedure. 20. The Contracting Authority did not conduct preliminary market consultations. 21. The Contracting Authority does not envisage the Contractor conducting a site visit or examining the documents necessary to perform the contract. 1.C. Medicines used in chemotherapy for the full range of registered indications and uses and for an indication defined by a clinical condition 2.C. Medicines used in chemotherapy for the full range of registered indications and uses and for an indication defined by a clinical condition 3.C. Medicines used in chemotherapy for the full range of registered indications and uses and for an indication defined by a clinical condition 4.C. Medicines used in chemotherapy for the full range of registered indications and uses and for an indication defined by a clinical condition 5.C. Medicines used in chemotherapy for the full range of registered indications and uses and for an indication defined by a clinical condition 6.Products registered in Poland, items 1–5 reimbursed (C. Medicines used in chemotherapy for the full range of registered indications and uses and for an indication defined by a clinical condition) 7.C. Medicines used in chemotherapy for the full range of registered indications and uses and for an indication defined by a clinical condition 8.C. Medicines used in chemotherapy for the full range of registered indications and uses and for an indication defined by a clinical condition 9.C. Medicines used in chemotherapy for the full range of registered indications and uses and for an indication defined by a clinical condition 10.C. Medicines used in chemotherapy for the full range of registered indications and uses and for an indication defined by a clinical condition 11.C. Medicines used in chemotherapy for the full range of registered indications and uses and for an indication defined by a clinical condition 12.C. Medicines used in chemotherapy for the full range of registered indications and uses and for an indication defined by a clinical condition 13.C. Medicines used in chemotherapy for the full range of registered indications and uses and for an indication defined by a clinical condition 14.C. Medicines used in chemotherapy for the full range of registered indications and uses and for an indication defined by a clinical condition 15.C. Medicines used in chemotherapy for the full range of registered indications and uses and for an indication defined by a clinical condition 16.C. Medicines used in chemotherapy for the full range of registered indications and uses and for an indication defined by a clinical condition 17.C. Medicines used in chemotherapy for the full range of registered indications and uses and for an indication defined by a clinical condition 18.C. Medicines used in chemotherapy for the full range of registered indications and uses and for an indication defined by a clinical condition 19.Product available in Polish packaging, reimbursement possible under RDTL 20.C. Medicines used in chemotherapy for the full range of registered indications and uses and for an indication defined by a clinical condition 21.C. Medicines used in chemotherapy for the full range of registered indications and uses and for an indication defined by a clinical condition 22.C. Medicines used in chemotherapy for the full range of registered indications and uses and for an indication defined by a clinical condition 23.C. Medicines used in chemotherapy for the full range of registered indications and uses and for an indication defined by a clinical condition 24.C. Medicines used in chemotherapy for the full range of registered indications and uses and for an indication defined by a clinical condition 25.C. Medicines used in chemotherapy for the full range of registered indications and uses and for an indication defined by a clinical condition 26.C. Medicines used in chemotherapy for the full range of registered indications and uses and for an indication defined by a clinical condition 27.C. C. Medicines used in chemotherapy for the full range of registered indications and uses and for an indication defined by a clinical condition 28.C. Medicines used in chemotherapy for the full range of registered indications and uses and for an indication defined by a clinical condition 29.C. Medicines used in chemotherapy for the full range of registered indications and uses and for an indication defined by a clinical condition 30.C. Medicines used in chemotherapy for the full range of registered indications and uses and for an indication defined by a clinical condition 31.C. Medicines used in chemotherapy for the full range of registered indications and uses and for an indication defined by a clinical condition 32. B. Medicines and foodstuffs for special nutritional purposes available under a drug program 33.C. Medicines used in chemotherapy for the full range of registered indications and uses and for an indication defined by a clinical condition 34.B. Medicines and foodstuffs for special nutritional purposes available under a drug program 35.B. Medicines and foodstuffs for special nutritional purposes available under a drug program 36.C. Medicines used in chemotherapy for the full range of registered indications and uses and for an indication defined by a clinical condition 37.B. B. Medicines and foodstuffs for special nutritional purposes available under a drug program 38.B. Medicines and foodstuffs for special nutritional purposes available under a drug program 39.B. Medicines and foodstuffs for special nutritional purposes available under a drug program 40.B. Medicines and foodstuffs for special nutritional purposes available under a drug program 41.B. Medicines and foodstuffs for special nutritional purposes available under a drug program 42.B. Medicines and foodstuffs for special nutritional purposes available under a drug program 43.B. Medicines and foodstuffs for special nutritional purposes available under a drug program 44.B. Medicines and foodstuffs for special nutritional purposes available under a drug program 45.B. Medicines and foodstuffs for special nutritional purposes available under a drug program 46.B. Medicines and foodstuffs for special nutritional purposes available under a drug program 47.B. Medicines and foodstuffs for special nutritional purposes available under a drug program 48.B. Medicines and foodstuffs for special nutritional purposes available under a drug program 49.B. Medicines and foodstuffs for special nutritional purposes available under a drug program 50.B. Medicines and foodstuffs for special nutritional purposes available under a drug program 51.B. Medicines and foodstuffs for special nutritional purposes available under drug program B162 52.B. Medicines and foodstuffs for special nutritional purposes available under a drug program 53.B. Medicines and foodstuffs for special nutritional purposes available under a drug program 54. B. Medicines and foodstuffs for special nutritional purposes available under a drug program 55. B. Medicines and foodstuffs for special nutritional purposes available under a drug program 56.Medicines from named-patient import or with marketing authorisation 57.Medicines from named-patient import or with marketing authorisation 58.Medicines from named-patient import or with marketing authorisation 59.Medicines from named-patient import or with marketing authorisation 60.Medicines from named-patient import or with marketing authorisation 61.Medicines from named-patient import or with marketing authorisation 62.Medicines from named-patient import or with marketing authorisation 63.Medicines from named-patient import or with marketing authorisation 64.RDTL 65.General-purpose medicine 66.General-purpose medicine 67.General-purpose medicine 68.General-purpose medicine 69.General-purpose medicine 70.General-purpose medicine 71.General-purpose medicine 72.General-purpose medicine 73.General-purpose medicine 74.General-purpose medicine 75.General-purpose medicine 76.General-purpose medicine 77.General-purpose medicine 78.General-purpose medicine 79.General-purpose medicine 80.Oil-based contrast agent Procedure: open. Review the original TED notice for the complete requirement, lots, amendments and attachments.